Drug Profile
Factor VIII/von Willebrand factor - Octapharma
Alternative Names: Eqwilate; Human factor VWF/FVIII concentrate; WilateLatest Information Update: 24 Jan 2024
Price :
$50
*
At a glance
- Originator Octapharma
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Factor VIII replacements; Von willebrand factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia A; Von Willebrand disease
Most Recent Events
- 22 Jan 2024 Adverse events and efficacy data from a phase III WIL-31 trial von Willebrand Disease were released by the Deciphera Pharmaceuticals
- 12 Dec 2023 Launched for Von Willebrand disease (In adolescents, In children, In adults) in USA (IV)
- 09 Dec 2023 efficacy and adverse events data from the trial was presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)